在基层医院应用替格瑞洛治疗急性冠脉综合征临床效果及安全性研究

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (614 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical efficacy and safety of Ticagrelor in the treatment of patients with acute cornoary syndrome(ACS) in the basic level hospital. Methods A total of 97 patients with acute coronary syndrome was analyzed retrospectively in Beijing Yanqing Hospital from January 2015 to May 2017. According to dual antiplatelet therapy, they were divided into Ticagrelor group (n = 49, treated with Ticagrelor combined with Aspirin) and Clopidogrel group (n = 48, treated with Clopidogrel combined with Aspirin). Major adverse cardiac events (MACE), the risk of bleeding and adverse drug reactions(ADR) were compared after a follow-up of 6 months. Results Compared with the Clopidogrel group(14.58%), the incidence of MACE of Ticagrelor group (2.04%) was significant decreased and there was significant difference (P < 0.05). But there was no significant difference in the incidence of bleeding event rates between the two groups (P > 0.05). Compared with the clopidogrel group (6.25%), the ADR of ticagrelor group (18.4%) was increased, but there was no statistically significant difference(P > 0.05). Conclusion Ticagrelor combined with Aspirin can decrease the MACE incidence of ACS and do not increase the risk of bleeding. It is safe, effective and worth popularizing in the basic level hospital.

Key words： Coronary heart disease Ticagrelor Safety Efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HE Xiaolei

Cite this article:

HE Xiaolei. A study of the clinical efficacy and safety of Ticagrelor in the treatment of acute coronary syndrome in the basic level hospital[J]. 中国医药导报, 2018, 15(22): 92-95.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I22/92

[1] 李康博，刘晓坤，张琦，等.低剂量替格瑞洛治疗稳定型冠心病患者的疗效及安全性评价[J].复旦学报：医学版，2016，43（2）：164-169.
[2] Anderson SD，Shah NK，Yim J，et al. Efficacy and safety of tieagrelor：a reversible P2Y12 recepetor antagonist [J]. Ann Pharmacother，2010，44（3）：524-537.
[3] 刘娟，颜红兵，宋莉，等.急性冠脉综合征患者院外服用替格瑞洛现状调查分析[J].中华医学杂志，2017，97（15）：1165-1169.
[4] 贺学魁，赵英娟.替格瑞洛改善NSTE-ACS患者PCI术后氯吡格雷抵抗的研究[J].中国循证心血管医学杂志，2017，9（2）：222-224，227.
[5] 侯方杰，刑明青，管军，等.替格瑞洛在急诊PCI术中应用的疗效及安全性观察[J].中国循证心血管医学杂志，2015，7（4）：533-536.
[6] 谢立，张文颖.我院替格瑞洛致不良反应108例分析[J].中国药房，2016，27（29）：4085-4087.
[7] 中华医学会心血管病分会，中华心血管病杂志编辑委员会，中国循环杂志编辑委员会.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志，2001，29（12）：705-720.
[8] Park Y，Franchi F，Rollini F，et al. Dual antiplatelet therapy after coronary stenting [J]. Expert Opin Pharmacother，2016，17（13）：1775-1787.
[9] 程庆强，高洁，任艺虹，等.老年冠心病患者服用替格瑞洛与氯吡格雷出血风险比较[J].中国老年器官疾病杂志，2016，15（12）：881-885.
[10] 师树田，聂绍平.替格瑞洛在急性冠脉综合征患者中的应用[J].中国介入心脏病学杂志，2014，22（7）：452-455.
[11] Ramaraj R，Movahed MR，Hashemzadeh M. Novel antiplatel agent ticagrelor in the management of acute coronary syndrome [J]. Interv Cardiol，2011，24：199-207.
[12] Storey RF，Angiolillo DJ，Patil SB，et al. Inhibitory effects of ticagre，ronary syndrome；the PLATO（PLATelet inhibition and Patient Outcomes）PLATELET substudy [J]. J Am Coll Cardiol，2010，56（18）：1456-1462.
[13] 王贺阳，苏晞，韩雅玲，等.替格瑞洛在急性冠脉综合征患者中应用的安全性和有效性分析[J].中国循证心血管医学杂志，2015，7（4）：468-471.
[14] Nylander S，Femia EA，Scavone M，et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism [J]. Thromb Haemost，2013，11（10）：1867-1876.
[15] VAN Giezen JJ，Nilsson I，Berntsson P，et al. Ticagrelor binds to human P2Y12 indepently from ADP but antagonize ADP induced receptor signaling and platelet aggregation [J]. Thromb Haemost，2009，7（9）：1556-1565.
[16] Sinhal AR，Aylward PE. New antiplatelet agents and the role of platelet funtion tseting in acute coronary syndrome [J]. Cli Ther，2013，35（8）：1064-1068.
[17] 吴龙梅.CYP2C19基因多态性指导下的抗血小板个体化治疗[J].中国循证心血管医学杂志，2015，7（2）：207-210.
[18] 许骥，华琦，胡少东，等.替格瑞洛在老年STAMI患者急诊PCI中的疗效与安全性分析[J].首都医科大学学报，2015，36（1）：73-77.
[19] 夏经钢，曲杨，徐东，等.替格瑞洛对急性ST段抬高型心肌梗死患者行急诊介入治疗的中期随访[J].北京大学学报：医学版，2015，47（3）：494-498.
[20] 叶明，王喜福，贾平，等.替格瑞洛对急性非ST段抬高型心肌梗死患者经皮冠状动脉介入治疗术后的疗效观察与安全性分析[J].中华医学杂志，2017，97（43）：3376-3379.
[21] Parodi G，Storey RF. Dyspnoea management in acute coronary syndrome patients treat with ticagrelor [J]. Eur Heart J Acute Cardiovase Care，2015，4（6）：555-560.
[22] Kotsia A，Brilakis ES，Held C，et al. Extent of coronary artery disease and outcome after ticagrelor administration in patients with an acute coronary syndrome：Insights from the Platelet inhibition and patient outcomes（PLATO）trial [J]. Am Heart J，2014，168（1）：68-75.
[23] 邵春丽，颜红兵，乔树宾，等.替格瑞洛相关呼吸困难的调查分析[J].中国介入心脏病学杂志，2015，23（2）：85-88.
[24] 梁鹏，许国耀，皮林，等.北京市社区门诊冠心病支架术后患者治疗现状调查[J].中国医刊，2017，52（12）：48-50.
[25] 谢东君，刘伟，李博，等.替格瑞洛致药物性皮疹1例分析[J].基层医学论坛，2017，21（10）：1288-1289.